Trial Profile
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Sotuletinib (Primary) ; Spartalizumab (Primary)
- Indications Advanced breast cancer; Glioblastoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis Pharma KK; Novartis Pharmaceuticals
- 08 Dec 2022 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record
- 05 Dec 2022 Status changed from active, no longer to discontinued.
- 30 Nov 2022 Planned End Date changed from 21 Nov 2022 to 1 Dec 2022.